|
|||||
|
|
Initial experience with CMC‐544 (inotuzumab ozogamicin) in pediatric patients with relapsed B‐cell acute lymphoblastic leukemia |
|
| Authors: | Michael Rytting MD Lisa Triche APN Deborah Thomas MD Susan O'Brien MD Hagop Kantarjian MD |
| Affiliation: | 1. Department of Pediatrics, The University of Texas MD Anderson Cancer Center, , Texas;2. Department of Leukemia, The University of Texas MD Anderson Cancer Center, , Texas |
| Abstract: | |
| Keywords: | acute lymphoblastic leukemia CD 22 CMC‐544 relapse |